Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;53(4):302-9.
doi: 10.1097/MLR.0000000000000330.

Patterns of cancer care costs in a country with detailed individual data

Affiliations

Patterns of cancer care costs in a country with detailed individual data

Tony Blakely et al. Med Care. 2015 Apr.

Erratum in

  • Med Care. 2015 Jun;53(6):560

Abstract

Objective: To determine health system expenditure on cancers by time since diagnosis using data for an entire country.

Methods: New Zealand cancer registry data was linked to hospitalization, pharmaceutical, outpatient, general practice, laboratory, and other datasets, with costs ascribed to each event occurring in 2006-2011. "Excess" cancer costs were estimated by subtracting "expected costs" for citizens without cancer from the "total cost" for cancer patients ($2011 inflation-adjusted). Gamma regressions were used to estimate costs per person-month.

Results: For first adult cancer diagnosed that the excess cost per person was between US$3400 and US$4300 in the first month postdiagnosis (varied by sex and age), fell to US$50-US$150 per month at 2 or more years postdiagnosis (excluding those within a year of death), but increased again if dying from their cancer (US$3800-US$8300 in the last month of life). Such patterns varied by cancer, for example, in the first month postdiagnosis for 65 year olds it varied 20-fold from US$800 for prostate to US$15,900 for brain cancer. Per diagnosed case, total excess costs varied from US$5000 (melanoma) to US$66,000 (bone and connective tissue) [Corrected]. Excess cancer costs made up 6.5% of total Vote:Health expenditure in 2010-2011, with colorectal (14.7%), breast (14.4%) being the top 2 contributors, and prostate, non-Hodgkin lymphoma, leukemia, and lung each contributing about 6%.

Conclusions: Costs vary substantially by time since diagnosis and cancer type. The results and regression equations reported in this paper can be used in modeling requiring cancer costs by time since diagnosis and proximity to death.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Excess health system cost per person per month of “first adult cancer” diagnosis by time preceding and postdiagnosis, separating off the 12 months before death from cancer, by sex and age. Error bars are 95% confidence intervals. Costs in NZ$, inflation-adjusted to 2011, using regression modeling of 2006–2011 data to predict 2011 values.
FIGURE 2
FIGURE 2
Excess health system costs per person per month for multiple cancers, compared across cancers for 65-year-old males (or females if female-only cancer) for: first month postdiagnosis, and 1–5 months postdiagnosis. Error bars are 95% confidence intervals. Costs in NZ$, inflation-adjusted to 2011.
FIGURE 3
FIGURE 3
Association of annual excess costs by cancer per diagnosed case, with the 5-year relative survival (RS) ratio for that cancer type. Line is ordinary least squares regression line for equation: cost=16128+(195869×RS)−(214145×RS); where P for RS and RS coefficients were 0.004 and 0.001, respectively. RSR indicate relative survival risk.

References

    1. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. - PubMed
    1. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87:935–943. - PMC - PubMed
    1. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Eng J Med. 2011;364:2060–2065. - PMC - PubMed
    1. Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Aff. 2012;31:700–708. - PubMed
    1. Jönsson B. Technology assessment for new oncology drugs. Clin Cancer Res. 2013;19:6–11. - PubMed

Publication types